Cullinan Therapeutics (CGEM) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Replimune Group (REPL) has outperformed Cullinan Therapeutics (CGEM) over the past year, gaining 183.9% versus a gain of 165.4%. Over five years, CGEM leads with a -37.5% price change compared with -56.2% for REPL. Replimune Group is the larger company by market cap ($1.24 billion vs $960.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | REPL |
|---|---|---|
| Share price | $15.63 | $13.20 |
| Market cap | $960.59M | $1.24B |
| 1-day change | -3.82% | -0.38% |
| YTD return | +51.01% | +35.80% |
| 1-year return | +165.37% | +183.87% |
| 5-year return | -37.48% | -56.22% |
| EPS (TTM) | $-3.11 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.19 | $16.33 |
| 52-week low | $5.85 | $1.50 |
| Distance from 52-week high | -32.60% | -19.17% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +114.01% | +47.73% |
| Average volume | 868.12K | 4.20M |
| Shares outstanding | 61.46M | 94.22M |
| Employees | 109 | 465 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed CGEM by 18.5 percentage points over the past year.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Healthcare · Biotechnology · 109 employees
About Replimune Group
REPL stock →Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Healthcare · Biotechnology · 465 employees
CGEM vs REPL FAQ
Which is bigger, Cullinan Therapeutics or Replimune Group?
Replimune Group (REPL) is larger, with a market capitalization of $1.24B compared with $960.59M for Cullinan Therapeutics (CGEM).
Which stock has performed better over the past year, CGEM or REPL?
REPL returned +183.87% over the past 12 months, compared with +165.37% for CGEM (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and Replimune Group in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.